2-Propen-1-one, 1-[(3R)-3-[[5-cyclopropyl-2-[[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]- manufacturers
- JAK3/BTK-IN-2
-
-
2026-07-27
- CAS:2674036-93-0
- Purity: 99.64%
- Supply Ability: 10g
|
| | 2-Propen-1-one, 1-[(3R)-3-[[5-cyclopropyl-2-[[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]- Basic information |
| | 2-Propen-1-one, 1-[(3R)-3-[[5-cyclopropyl-2-[[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]- Chemical Properties |
| density | 1.50±0.1 g/cm3(Predicted) | | pka | 13.92±0.50(Predicted) |
| | 2-Propen-1-one, 1-[(3R)-3-[[5-cyclopropyl-2-[[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]- Usage And Synthesis |
| Uses | JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)[1] | | References | [1] Guobao Zhang, et al. Pyrimidopyrroles. Patent WO2021147952A1. |
| | 2-Propen-1-one, 1-[(3R)-3-[[5-cyclopropyl-2-[[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]- Preparation Products And Raw materials |
|